Navigation Links
Metabolex Announces Election of Kurt von Emster to Board of Directors
Date:4/22/2009

HAYWARD, Calif., April 22 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new therapeutics for the treatment of diabetes and related metabolic disorders, announced that Kurt von Emster has been elected to its Board of Directors.

Mr. von Emster currently serves as a Managing Director of venBio. From November 2000 to March 2009, Mr. von Emster was Managing Director of MPM BioEquities and a Portfolio Manager for the MPM BioEquities Fund. From July 1989 to November 2000, Mr. von Emster was with the Franklin Templeton Group, most recently as a Vice President and Portfolio Manager. Mr. von Emster is currently a member of the board of directors at Somaxon Pharmaceuticals, Inc., and Facet Biotech, both public biotechnology companies. Mr. von Emster is a Chartered Financial Analyst (CFA), a member of the Association for Investment Management and Research and of the Security Analysts of San Francisco. Mr. von Emster received his B.S. degree from the University of California at Santa Barbara.

"Mr. von Emster brings to the Board the perspective of a seasoned private and public company investor," said Harold Van Wart, Ph.D., president and chief executive officer of Metabolex. "We look forward to his input and expertise as the company continues to build upon its recent clinical successes." Mr. von Emster's appointment follows the resignation of Rob Chess from the Board of Directors. Dr. Van Wart added, "I would like to thank Rob for his many valuable contributions to Metabolex during his Board tenure."

About Metabolex

Metabolex is a privately-held biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, with an emphasis on type 2 diabetes. Metabolex has drawn on its deep understanding of diabetes to create a large database of genes in
'/>"/>

SOURCE Metabolex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Metabolex Announces Positive Results From Phase 1a Clinical Trial of MBX-2982
2. Two Metabolex Projects Recognized in Windhovers Top 10 Lists for Partnering Opportunities
3. Metabolex Names Zhao, Martin to Executive Posts
4. Metabolex Appoints Donald Hill as Chief Financial Officer
5. Yongye Biotechnology Announces Preliminary Results for its Fiscal Quarter Ended March 31, 2009
6. HUYA Bioscience Announces Strategic Alliance With Abbott on Drug and Biomarker Development Candidates From China
7. Bio-Matrix Scientific Group, Inc. Announces Preferred Stock Dividend and Spinoff of Wholly-Owned Subsidiary, Entest Biomedical, Inc.
8. Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models
9. E&K Scientific Announces New Accuflow Product Line
10. Thoratec Announces Filing of PMA Seeking Destination Therapy Approval for HeartMate II(R)
11. International Society for Medical Publication Professionals (ISMPP) Announces First CMPP Exam Window Closes, Next Opportunity in September
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013 PI’s new LPS-24 ... provide 15 mm travel range with closed-loop sensor ... dimensions make these new positioners the ideal choice ... vacuum rated version is also available. , ... datasheets can be found at: , http://www.physikinstrumente.com/en/products/prdetail.php?sortnr=1000745&prw-lps24 ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 On April ... trips to supermarkets to search for the growing antibiotic ... aisles. Results from a year long study were released ... in foods, specifically meats, over previous years. For those ... the growth of antibiotic resistant bacteria in food, may ...
(Date:5/23/2013)... May 23, 2013  Verenium Corporation (Nasdaq: ... the development and commercialization of high-performance enzymes, today announced ... Officer, will present at two upcoming conferences. ... present at the Second Annual Marcum LLP Microcap Conference ... Hotel in New York City.  The presentation is scheduled ...
(Date:5/23/2013)... 2013 Bed bugs already cost Alton Housing ... still ongoing, a report from kmov.com suggested that the said ... bug treatment. Meanwhile, to be of help, My Cleaning Products ... bed bug exterminator service. , The report, which ... so far spent $35,000 for bed bug elimination, ...
Breaking Biology Technology:Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3Bed Bug Exterminator Service Could Cost AHA $250K, My Cleaning Products Gives Tips How to Save Apartments from Costly Bed Bug Treatment 2
... June 19 Isolagen(TM), Inc. announced on June 16, ... Company,s wholly owned subsidiary, each filed a voluntary petition ... Bankruptcy Code in the United States Bankruptcy Court for ... and Isolagen Technologies intend to continue to manage and ...
... , , , Industry ... Clinical Sites, Research Sponsors and Regulators through Utilization of ... Greenway Medical Technologies, a leading provider of an ... solution, today announced its participation in the Drug Information ...
... conducted by Novartis evaluating safety and efficacy of Albuferon administered ... genotypes 2 and 3 hepatitis C - , , ... HGSI ) today announced that Novartis has completed ... to evaluate the safety and efficacy of Albuferon(R) (albinterferon alfa-2b) ...
Cached Biology Technology:Isolagen, Inc. Announces Receipt of Interim Order from Bankruptcy Court Approving DIP Motion 2Isolagen, Inc. Announces Receipt of Interim Order from Bankruptcy Court Approving DIP Motion 3Greenway Medical Technologies To Display Live Interoperability Implementations at 2009 DIA Show 2Greenway Medical Technologies To Display Live Interoperability Implementations at 2009 DIA Show 3Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R) 2Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R) 3Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R) 4
(Date:5/22/2013)... bacteria is responsible for legionellosis, an infectious disease that ... this pathogen has developed a complex method enabling it ... thus avoiding these acting against the infectious bacteria. , ... bioGUNE, in which teams from the National Institute of ... Centre in Barcelona (BSC) have also participated, has described ...
(Date:5/21/2013)... for a long time that some creatures evolve more ... for plants. But it may be that height plays ... and the U. S. National Evolutionary Synthesis Center. ... in the journal Nature Communications , Lanfear and ... Drawing from a database of global patterns in plant ...
(Date:5/21/2013)... of pharmaceuticals can both prevent and treat Alzheimer,s Disease ... ligands," are currently used for certain types of neuroimaging. ... in young adult mice when pathology was at an ... quite severe," said lead researcher Christian Pike of the ... of pathology and improved behavior at both ages." , ...
Breaking Biology News(10 mins):Mechanism discovered which aids Legionella to camouflage itself in the organism 2Small but speedy: Short plants live in the evolutionary fast lane 2Drugs found to both prevent and treat Alzheimer's disease in mice 2
... Ga. Predicting the risk of extinction is a complicated ... sites. Researchers at the University of Georgia and Tulane University ... more accurate. Their work appears in the early online edition ... "The concern is that for a lot of species, we ...
... and why students smoke might lead to the development of ... Missouri. In an article published in the journal ... partying, drinking and work prompted college students to recall their ... start of the semester and on weekends. "Students ...
... Washington, D.C.-- New research suggests a pattern of outpatient ... in the Southeast --a problem that could accelerate the ... according to Extending the Cure, a project of the ... findings come out just as the Centers for Disease ...
Cached Biology News:New model more accurately describes migratory animals' extinction risk 2Research reveals when and why students smoke in effort to help them quit 2Alarming pattern of antibiotic use in the southeastern United States 2Alarming pattern of antibiotic use in the southeastern United States 3
... Recombinant Enterokinase (rEK) is a highly purified ... enterokinase, a serine protease which recognizes the ... (AspAspAspAspLys?) and has similar enzymatic activity (1). ... and purified to yield the highest activity ...
Angiotensin Converting Enzyme [Porcine Kidney, ACE, Peptidyl-dipeptidase A]...
The bench-top stand comfortably holds up to 6 Finnpipette Digital single- and multichannel pipettes. The crossbars are made of a grippy material to keep the pipettes firmly in place. Individual shelf...
... a serine/threonine phosphatase isolated from human red ... heterodimer of 60kDa (A) and 36kDa (C) ... the a-subunit of phosphorylase kinase. With its ... specificity and may play a regulatory role ...
Biology Products: